ArticleScience translational medicine2022
Platelet-mimicking procoagulant nanoparticles augment hemostasis in animal models of bleeding.
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 67 citations in OpenAlex.
- Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Lyophilized Synthetic Platelets: In Vitro Characterization and In Vivo Evaluation in Mouse Thrombocytopenia Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oral alginate microspheres deliver Rg3/aspirin liposomes to modulate foam cells and gut microbiota in atherosclerosis.Journal of nanobiotechnology · 2026Article
- Continuum and discrete modeling of binding-site distribution-mediated reactions on lipid surfaces.Biophysical journal · 2026Article
- Recombinant haemostatic protein for therapeutic substitution of platelet function via tripartite haemostatic mechanisms in thrombocytopenic male mice.Nature communications · 2026Article
- An Injectable Hybrid Gelatin Methacryloyl/Polydopamine Nanoparticle Bioink for Rapid Hemostasis Applications.ACS applied bio materials · 2026Article
- Engineering design of platelet-mimicking therapeutic systems: multilevel biomimicry, gating strategies, and translational boundaries.Frontiers in bioengineering and biotechnology · 2026Review
- Total thrombus formation system exploration of primary hemostasis in cirrhotic patients.Research and practice in thrombosis and haemostasis · 2026Article
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
- Platelet-derived biomimetic nanoplatforms: a promising drug delivery strategy for cardiovascular disease.Journal of nanobiotechnology · 2025Review
- Review
- Accurate Delivery of Mesenchymal Stem Cell Spheroids With Platelet-Rich Fibrin Shield: Enhancing Survival and Repair Functions of Sp-MSCs in Diabetic Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeted codelivery of nitric oxide and hydrogen sulfide for enhanced antithrombosis efficacy.Bioactive materials · 2025Article
- Novel Platelet-Like PLGA-PSP Nanoparticles Based on Platelet-Specific Peptides Alleviated Traumatic Hemorrhage.International journal of nanomedicine · 2025Article
- Injectable and rapidly expandable thrombin-decorated cryogels achieve rapid hemostasis and high survival rates in a swine model of lethal junctional hemorrhage.Bioactive materials · 2024Article
- Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress.Research and practice in thrombosis and haemostasis · 2024Article
- The intriguing role of platelets as custodians of brain-derived neurotrophic factor.Research and practice in thrombosis and haemostasis · 2024Article
- Article
- Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy.Pharmaceutics · 2023Review
- In Vivo Validation of a Mechanically Adaptive Microfluidic Intracortical Device as a Platform for Sustained Local Drug Delivery.Frontiers in biomaterials science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
Treatment of bleeding disorders using transfusion of donor-derived platelets faces logistical challenges due to their limited availability, high risk of contamination, and short (5 to 7 days) shelf life. These challenges could be potentially addressed by designing platelet mimetics that emulate the adhesion, aggregation, and procoagulant functions of platelets. To this end, we created liposome-based platelet-mimicking procoagulant nanoparticles (PPNs) that can expose the phospholipid phosphatidylserine on their surface in response to plasmin. First, we tested PPNs in vitro using human plasma and demonstrated plasmin-triggered exposure of phosphatidylserine and the resultant assembly of coagulation factors on the PPN surface. We also showed that this phosphatidylserine exposed on the PPN surface could restore and enhance thrombin generation and fibrin formation in human plasma depleted of platelets. In human plasma and whole blood in vitro, PPNs improved fibrin stability and clot robustness in a fibrinolytic environment. We then tested PPNs in vivo in a mouse model of thrombocytopenia where treatment with PPNs reduced blood loss in a manner comparable to treatment with syngeneic platelets. Furthermore, in rat and mouse models of traumatic hemorrhage, treatment with PPNs substantially reduced bleeding and improved survival. No sign of systemic or off-target thrombotic risks was observed in the animal studies. These findings demonstrate the potential of PPNs as a platelet surrogate that should be further investigated for the management of bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.